Ep 81: IGNYTE trial (RP1 + nivo)

from Melanoma Matters · host Melanoma Matters Pod

SummaryThe conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into clinical trial interpretation and treatment efficacy (and incorrect graphs).TakeawaysClinical Trial DataTreatment EfficacyChapters00:00 Introduction to IGNYTE Study14:04 Response Rate and Safety Profile25:17 RNA-seq Analysis and Toxicity

Episode metadata supplied by the publisher feed · Published Feb 13, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Ep 81: IGNYTE trial (RP1 + nivo)

0:00 32:38

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Melanoma Matters?

This episode is 32 minutes long.

When was this Melanoma Matters episode published?

This episode was published on February 13, 2026.

Can I download this Melanoma Matters episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!